KLP Kapitalforvaltning AS bought a new stake in Nuvalent, Inc. (NASDAQ:NUVL – Free Report) during the 4th quarter, Holdings Channel reports. The firm bought 7,600 shares of the company’s stock, valued at approximately $595,000.
Other hedge funds have also made changes to their positions in the company. Commonwealth Equity Services LLC increased its position in shares of Nuvalent by 13.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 2,618 shares of the company’s stock worth $205,000 after purchasing an additional 309 shares during the last quarter. KBC Group NV boosted its stake in Nuvalent by 61.1% during the fourth quarter. KBC Group NV now owns 1,587 shares of the company’s stock worth $124,000 after buying an additional 602 shares during the period. US Bancorp DE acquired a new stake in shares of Nuvalent during the fourth quarter valued at about $90,000. M&T Bank Corp raised its stake in shares of Nuvalent by 16.4% in the 4th quarter. M&T Bank Corp now owns 8,473 shares of the company’s stock valued at $664,000 after acquiring an additional 1,192 shares during the period. Finally, MetLife Investment Management LLC lifted its holdings in shares of Nuvalent by 6.7% in the 3rd quarter. MetLife Investment Management LLC now owns 19,737 shares of the company’s stock worth $2,019,000 after acquiring an additional 1,231 shares during the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.
Insider Activity at Nuvalent
In other news, insider Henry E. Pelish sold 2,483 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $79.68, for a total transaction of $197,845.44. Following the completion of the transaction, the insider now directly owns 59,981 shares of the company’s stock, valued at approximately $4,779,286.08. This represents a 3.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO James Richard Porter sold 17,301 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $79.68, for a total value of $1,378,543.68. Following the completion of the transaction, the chief executive officer now owns 249,062 shares in the company, valued at approximately $19,845,260.16. The trade was a 6.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 108,800 shares of company stock valued at $8,437,464 over the last 90 days. 12.52% of the stock is owned by corporate insiders.
Nuvalent Trading Up 3.6 %
Nuvalent (NASDAQ:NUVL – Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). On average, equities analysts forecast that Nuvalent, Inc. will post -3.86 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on NUVL. UBS Group upgraded shares of Nuvalent from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Nuvalent in a research note on Monday, March 3rd. Finally, Wedbush reiterated an “outperform” rating and issued a $115.00 price objective on shares of Nuvalent in a report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $113.44.
Read Our Latest Stock Analysis on NUVL
Nuvalent Company Profile
Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.
Read More
- Five stocks we like better than Nuvalent
- Where to Find Earnings Call Transcripts
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How to invest in marijuana stocks in 7 steps
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Why Invest in 5G? How to Invest in 5G Stocks
- Analyst Targets Signal More Growth in CrowdStrike Stock
Want to see what other hedge funds are holding NUVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvalent, Inc. (NASDAQ:NUVL – Free Report).
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.